TRANSLATIONAL MEDICINEIN ZURICH

CONFERENCE BOOKLET

JANUARY 22ND, 2018TECHNOPARK ZURICH

A LIFE SCIENCE ZURICH BUSINESS NETWORK INITIATIVE

#LSZIMPACT

© N

orbe

rt W

ey, U

SZ

INNOVATION

MADE IN

ZURICH

WELCOME TO ZURICH

Zurich offers a vibrant and dynamic ecosystem for

the entrepreneurial scene, especially in the field of

life sciences. The foundations for this are laid by the

two top-class universities, the University of Zurich

and the ETH Zurich. Together with the University

Hospitals and the Zurich University of Applied

Sciences (ZHAW), academic medicine covers a broad

spectrum of scientific disciplines and provides cut-

ting-edge transdisciplinary research – one important

aspect of innovation. In addition, internationally re-

nowned companies of the life science industry have

settled in the Zurich region. This environment is seeing

a growing number of spin-outs from the Universities in

the pharmaceutical, biotechnology and medical tech-

nology sectors. Thanks to its combination of academic

excellence, entrepreneurship and innovation, financial

strength, outstanding accessibility, a high level of se-

curity as well as a healthy economy, Zurich is one of

the leading centers of life sciences in Europe.

A core task of academic medicine is to design the

medicine of the future using innovative concepts,

new technologies and transdisciplinary know-how to

generate sustainable value for health promotion, health

prevention and the whole cycle of care. Decisive for

that is to make new technologies and therapies appli-

cable for patients and public. Translational Medicine

deals with the transition of new insights and products

from basic research and industrial development into

clinical application and is therefore an essential deter-

minant for cross-linking basic research and medical

use. In short, translational research builds the bridge

from bench-to-bedside and back. The close interaction

between universities, private companies and the pub-

lic sector provides ideal conditions for young entrepre-

neurs to perform this translation.

The first translational medicine conference «Life

Science Zurich Impact» promotes such interactions

by providing scientists from academia and industry a

platform to present their life sciences projects to po-

tential collaboration partners as well as to investors. It

is therefore an excellent opportunity to accelerate

the development of novel therapeutic strategies

and innovative concepts of health prevention for

the benefit of numerous patients in our aging society.

We take this occasion to wish the participants an excit-

ing conference with plenty of opportunities to expand

your personal network with valuable contacts.

Carmen Walker Späh

Government Councillor

Canton of Zurich

Head of the Depart-

ment for Economic

Affairs

Prof. Dr. Christoph Hock

Vice President for

Medicine

University of Zurich

© Z

üric

h To

uris

mus

AIM AND SCOPE OF THE CONFERENCE

Life Science Zurich Impact – Translational Medicine in Zurich is a one-day multi-track meeting providing

scientists from academia and industry a platform to present their life sciences projects to potential collab-

oration partners as well as investors. The focus lies on early stage projects in pharma, biotech and medtech in

the fields of cancer, immunology & infection and neurosciences. We believe that early interaction with potential

partners is a key success factor for research groups, young entrepreneurs and industry.

1-TO-1 PARTNERING

To promote networking, and to faciltiate the formation of new contacts and the initiation of new projects are major

goals of Life Science Zurich Impact – Translational Medicine in Zurich.

To this end, pre-arranged 20 minutes face-to-face meetings are coordinated by Enterprise Europe Network.

Register now for matchmaking at the conference webpage. During the conference, Nicolas Lentze from Enter-

prise Europe Network will offer on-site support.

INDUSTRY EXHIBITION

Please visit the booths in the exhibition area to learn about innovative products and services!

Open during the entire conference.

CONTACTS

General questions about the eventDanielle Spichiger

Business & Economic Development

Canton of Zurich

danielle.spichiger@vd.zh.ch

+41 43 259 49 86

Silvie Cuperus

Life Science Zurich

info@lifescience.uzh.ch

+41 44 635 35 01

Industry exhibitionTo book a booth in the exhibition area please contact

Angelika Rüegg

angelika.rueegg@vd.zh.ch

For questions about delivery/installation of material

please contact Marianna Lutz (Eventmanagement,

Stiftung TECHNOPARK® Zürich)

marianna.lutz@technopark.ch

+41 44 445 10 00

Partnering and matchmakingNicolas Lentze

Enterprise Europe Network Switzerland

nicolas.lentze@innosuisse.ch

+41 58 469 07 59

I CAN READ 5,000 NEW MEDICAL STUDIES A DAY AND STILL SEE PATIENTS.

With Watson and IBM Services, doctors on 5 continents can use clinical guidelines, medical literature, and data from patients to help them give advanced and personalized care. Find out more at ibm.com/you This is healthcare to the power of IBM.

IBM and its logo, ibm.com and Watson are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. See current list at ibm.com/trademark. Other product and service names might be trademarks of IBM or other companies. ©International Business Machines Corp. 2017.

IBM and its logo, ibm.com and Watson are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. See current list at ibm.com/trademark. Other product and service names might be trademarks of IBM or other companies. ©International Business Machines Corp. 2017.

ORGANIZERS

The Life Science Zurich Business Network is an

independent, non-profit association comprising play-

ers from universities, industry, economic develop-

ment, business clusters, and technology transfer. It

represents the life sciences cluster in the Zurich area

and supports and stimulates networking and collab-

orations between industry, academia, and the public

sector in the Zurich area and companies and organi-

sations abroad.

PARTNERS

SPONSORS Gold SPONSORS Silver

Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour

IBM Research

Pho

togr

aphy

: Oliv

ia J

anet

t

WE THANK OUR PARTNERS AND SPONSORS FOR THEIR ENGAGEMENT AND SUPPORT!

BioResearch

Advancing Research withBiologically Relevant Solutions

Our products and services support researchers through their cell biology process, from early research through drug discovery and cell therapy. We offer biologically relevant tools to quickly and easily generate decision driving data.

– Primary Cells and Media – Media and Reagents – Mycoplasma Detection and Prevention – Cell Analysis – Transfection – BioAssay Products and Services – Electrophoresis and Analysis

www.lonza.com/research© 2015 Lonza

GENERAL INFORMATION

Meeting venueTechnopark Zürich is located at the heart

of Zurich West

Technoparkstrasse 1, 8005 Zürich

www.technopark.ch

By car from

• St. Gallen/airport via Rosengartenstrasse,

Escher-Wyss-Platz (bridge), Hardturmstrasse,

Förrlibuckstrasse, Duttweilerstrasse (Toni-Molkerei

building), Pfingstweidstrasse, Technoparkstrasse.

• Bern/Basel: via Pfingstweidstrasse, Technopark-

strasse.

• Lucerne/Chur: via Hardbrücke, Geroldstrasse exit

ramp, Schiffbau, Technoparkstrasse.

• Zurich: via Escher-Wyss-Platz, Hardstrasse or Hard-

turmstrasse

Limited parking space is available at extra cost on

site. Further parking space is available in walking

distance:

• Parkhaus Pfingstweid (Welti-Furrer-Areal,

Pfingstweidstrasse 1, 8005 Zürich).

• Parkhaus P-West (Förrlibuckstr. 151, 8005 Zürich)

The site is best reached by public transport

• Tram no. 4 to Technopark, walk 2 minutes

• Tram no. 17 to Förrlibuckstrasse, walk 4 minutes

• Tram no. 13 or 17 to Escher-Wyss-Platz, walk

8 minutes

• Bus no. 33 to Schiffbau, walk 4 minutes

• Bus no. 72 to Schiffbau, walk 4 minutes

• S-Bahn lines S3 / S5 / S6 / S7 / S9/ S12 / S15 / S16

to Hardbrücke, walk 8 minutes

Internet accessVia WIFI/hotspot in public areas and event rooms.

Further information will be provided at the event.Stiftung TECHNOPARK® ZürichTechnoparkstrasse 1 | CH-8005 Zürich Tel +41 44 445 10 00 | info@technopark.ch www.technopark.ch

© Copyright TECHNOPARK® Immobilien AG, Technoparkstasse 1, 8005 Zürich 14. Oktober 2014

So finden Sie uns

Anreise mit öffentlichen Verkehrsmitteln › Förrlibuckstrasse (VBZ): Tram Nr. 17 (Fussweg Technopark­

strasse, gestrichelte Linie, durch Sulzer Escher­Wyss­Areal, 4 Min.)*

› Escher-Wyss-Platz (VBZ): Tram Nr. 4, 13 oder 17 (Fussweg, entlang Hardstrasse / Schiffbaustrasse, gestrichelte Linie, Technoparkstrasse, 8 Min.)*

› Technopark (VBZ): Tram 4 bis Technopark (Fussweg, gestrichelte Linie, Technoparkstrasse, 1 Min.)*

› Bus (VBZ) Nr. 33 bis Station Schiffbau (Fussweg, gestrichelte Linie, Technoparkstrasse, 4 Min.)*

› Bus (VBZ) Nr. 72 bis Station Schiffbau (Fussweg, gestrichelte Linie, Technoparkstrasse, 4 Min.)*

› S-Bahn Linien S3 / S5 / S6 / S7 / S9 / S12 / S15 / S16 (alle Linien mit Verbindungen zu Zürich­HB) oder diverse SBB­Linien von und nach Zürich­HB bis Station Hardbrücke (Fussweg entlang Hardstrasse, gestrichelte Linie, Technoparkstrasse, 8 Min.)*

* Taktfahrplan: zwischen 6.00 – 20.00 Uhr, alle 7.5 Min

Anreise mit privaten VerkehrsmittelnSehr beschränkte Anzahl gebührenpflichtiger Parkplätze in der Tiefgarage TECHNOPARK® Zürich, weitere Parkhäuser: P Pfingstweid und P West › von St.Gallen / Flughafen: über Rosengartenstrasse, Escher­

Wyss­Platz­(Brücke), Hardturmstrasse, Förrlibuckstrasse, Duttweilerstrasse (Toni­Areal / ZHdK), Pfingstweidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)

› von Bern / Basel: über Pfingstweidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)

› von Luzern/Chur: über Hardbrücke, Geroldrampe, Pfingst­weidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)

› von der City: via Escher­Wyss­Platz, Hardstrasse oder Hardturmstrasse (ausgezogene Linie)

› vom P+R Hardturm: Tram 17 (VBZ) nach Förrlibuckstrasse

Wegfahrt vom TECHNOPARK® Richtung Pfingstweidstrasse: nach Bern/BaselWegfahrt vom TECHNOPARK® Richtung Förrlibuckstrasse: nach St.Gallen/Flughafen/Luzern/Chur und Zürich-City

Eingang

Förrlibuckstrasse

Escher-Wyss-Platz

Giessereistrasse

Pfingstweidstrasse

Duttw

eile

rstra

sse

Dut

twei

lerb

rück

e

Hohlstrasse

Tech

nopa

rkst

rass

eFörrlibuckstrasse

Hards

trass

e

Heinrichstrasse

Josefstrasse

Limm

atstrasse

Turbinen-platz

Schiffbaustrasse

Geroldrampe

Hardturmstrasse

VBZ

Schiffbau

Technopark

TechnoparkZürich

Hardbrücke (S-Bahn)

VBZ

VBZ

VBZ

P

P

P West

Pfingstweid

LuzernChur N

St. GallenFlughafen

BernBasel

LimmatFörrlibuckstrasse

Conference Webpage:https://lsz-impact2018.b2match.io

#lszimpact

Johnson & Johnson Innovation Centres A flexible approach to advancing early-stage innovation

Johnson & Johnson Innovation seeks to find the best science and technology partners, no matter where they are, to solve the greatest unmet needs of our time. Positioned at the heart of the world’s most creative science hubs, we take a collaborative approach to partnering to advance early-stage innovation.

The next breakthrough idea can come from anywhere. Maybe it will come from you.Together we can transform ideas into healthcare solutions that change lives.

BECAUSE A GREAT IDEA CAN COME FROM ANYWHERE

@jnjinnovation

©Johnson & Johnson Innovation LLC 2017.

www.jnjinnovation.com

786207158-001_Innovation Press Ads_108x145_UK.indd 1 12/09/2017 13:41

8:00 - 9:00 Registration

9:00 - 9:10 Welcome Danielle Spichiger, Director Cluster Life Sciences, Business and Economic Development, Canton of Zurich; President, Life Science Zurich

Business Network Introduction Prof. Christoph Hock, Vice President Medicine, University of Zurich

9:10 - 9:40 Novel technologies create new molecules for accessing cutting-edge therapeutic concepts Prof. Andreas Plückthun, Professor of Biochemistry, UZH; Co-founder of Morphosys, Molecular Partners, G7/Heptares-Zurich

9:40 - 10:10 Lost in medical translation? Prof. Ralph Müller, Professor and Head Laboratory for Bone Biomechanics, ETH Zurich; Co-founder b-cube AG / Pearltec AG

10:10 - 10:30 Coffee break

10:30 - 12:00 Parallel sessions morning Overview + 4-5 short presentations + wrap-up and summary

CANCER IMMUNOLOGY & INFECTION NEUROSCIENCE

Prof. Bernd Bodenmiller, UZH

PD Dr. Irene Burger, USZ

Prof. Manfred Claassen, ETH Zurich

Prof. Anne Müller, UZH

Dr. Christian Rommel (CHAIR), Global Head of Oncology, Roche

Prof. Burkhard Becher, UZH

Dr. Mattias Ivarsson, CEO & Founder Inositec

Prof. Roland Martin (CHAIR), UZH & Wyss Zurich

Dr. Roch Ogier, Therapy Development Accelerator UZH

Jean-Philippe Tripet, Founder & Chairman ARAVIS

Prof. Alexandra Trkola, UZH

Prof. Frédéric Allain, ETH Zurich

PD Dr. Patrick Freund, UZH

Dr. Jan Grimm, CSO Neurimmune

Prof. Sebastian Jessberger, UZH

Prof. Lawrence Rajendran, UZH

Prof. Martin Schwab (CHAIR) / Dr. Roman Willi, NovaGo

12:00 - 13:30 Lunch break

TRANSLATIONAL MEDICINE IN ZURICH January 22nd, 2018, Technopark Zurich

MORNING PROGRAMME

Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour

13:30 - 15:00 Parallel sessions afternoon Overview + 4-5 short presentations + wrap-up and summary

CANCER IMMUNOLOGY & INFECTION NEUROSCIENCE

Dr. Chad Brokopp, CEO MabImmune

PD Dr. Stefano Ferrari, UZH

Dr. Christian Leisner, CEO CDR Life

PD Dr. Raffaella Santoro, UZH

Dr. Anne Schmidt, CEO Elthera

Prof. Simone Schürle (CHAIR), ETH Zurich

Prof. Onur Boyman (CHAIR), USZ

Dr. Louise Jopling, Senior Director Immunology Scientific Innovation, Johnson & Johnson Innovation

Dr. Jan Kisielow, ETH Zurich

Prof. Andreas Lutterotti, UZH & Wyss Zurich

Jean-Philippe Tripet, Swiss Entrepreneurs Fund

Dr. Tomas de Wouters, CEO PharmaBiome

Prof. Sven Hirsch, ZHAW Life Sciences and Facility Management

Dr. Sanjay Keswani, Global Head of Neuroscience, Ophthalmology & Rare Diseases, Roche

Prof. Isabelle Mansuy (CHAIR), UZH

Prof. Boris Quednow, UZH

Prof. Markus Rudin, ETH Zurich

Dr. Bechara Saab, CEO & Chief Scientist, Mobio Interactive

15:00 - 15:30 Coffee break

15:30 - 16:00 Hackers, Hipsters, Hustlers: Bio-Entrepreneurs in Zurich Prof. Roger Nitsch, Professor and Director Institute for Regenerative Medicine, UZH; Founder and President of the Board, Neurimmune

16:00 - 16:30 Cognitive Computing in Life Sciences Dr. Costas Bekas, Manager of Foundations of Cognitive Computing Group, IBM Research-Zurich

16:30 - 17:15 Panel discussion «Apple, IBM, Google and Co: the next Big Pharma?» Dr. Costas Bekas, Manager of Foundations of Cognitive Computing Group, IBM Research-ZurichNathan Hubbard, Director of Digital and PHC Partnering, Roche PartneringDr. Denis Schapiro, winner of the first «UZH BioEntrepreneur-Fellowship» 2017 Prof. Effy Vayena, Professor of Bioethics and Health Policy, ETH Zurich moderated by Barnaby Skinner, Data Journalist, Tamedia

17:15 - 17:30 Summary and Outlook Prof. Ernst Hafen, Institute of Molecular Systems Biology, ETH Zürich, President of BIO-TECHNOPARK Schlieren-Zurich and

MIDATA Genossenschaft Closing remarks Prof. Detlef Günther, Vice President Research and Corporate Relations, ETH Zurich

17:30 - 18:30 Apéro

TRANSLATIONAL MEDICINE IN ZURICH January 22nd, 2018, Technopark Zurich

AFTERNOON PROGRAMME

Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour

KEYNOTE SPEAKERS

Andreas Plückthun, a biochemist fo-

cused on the field of protein enginee-

ring, has been honoured by numerous

prestigious international awards. His

research contributed to enabling the

emergence of antibody engineering

and directed evolution. Studies on syn-

thetic antibodies have led to the first

fully synthetic antibody library. Moreo-

ver, he is cofounder of the biotechnolo-

gy companies Morphosys AG (Martins-

ried, Germany), Molecular Part ners AG

(Zurich-Schlieren, Switzer land) and G7

Therapeutics, recently acquired by Hep-

tares Therapeutics ( Zurich-Schlieren,

Switzerland).

Andreas Plückthun is a professor in the

Department of Biochemistry at the Uni-

versity of Zurich, and has been elected

member of the German Academy of

Science. He is one of the most highly

cited scientists at UZH of all fields, and

internationally in the field of protein re-

search.

Ralph Müller is a full Professor of Bio-

mechanics at the Department of Health

Sciences and Technology at ETH Zurich.

He studied electrical engineering at

ETH Zurich, where he also received his

doctoral degree in 1994. Professor Mül-

ler‘s research employs state-of-the-art

biomechanical testing and simulation

techniques as well as novel bioima-

ging and visualisation strategies for

musculoskeletal tissues. Today, these

techniques are successfully employed

for the quantitative assessment and

monitoring of structure function relati-

onships in tissue regeneration, growth

and adaptation. In 2008, Ralph Müller

founded two spin-off companies, Pearl-

tec AG, developing and marketing novel

patient positioning systems for medical

imaging procedures using patented

technology from ETH Zürich, and b-cu-

be AG, since 2013 a subsidiary of Scan-

co Medical AG.

Roger M. Nitsch, a neuroscientist

with a background in medicine, is re-

cognized as a pioneer of disease-mo-

difying therapeutic approaches for

neurodegenerative diseases with more

than 30 years of experience in Alzhei-

mer’s disease research. His main re-

search focus is the immunotherapy of

neurodegenerative diseases. He spe-

arheaded the development of Aduca-

numab, a human antibody for the tre-

atment and prevention of Alzheimer’s

disease. In addition, Roger M. Nitsch

is a founder and president of Neurim-

mune a biopharmaceutical company

dedicated to the development of im-

munotherapeutics for the treatment

and prevention of human disorders

with high unmet medical needs.

Costas Bekas is managing the Foun-

dations of Cognitive Computing group

at IBM Research-Zurich. He received

B. Eng., Msc and PhD diplomas, all

from the Computer Engineering & In-

formatics Department, University of

Patras, Greece, in 1998, 2001 and 2003

respectively. Between 2003-2005,

he worked as a postdoctoral associ-

ate with Professor Yousef Saad at the

Computer Science & Engineering De-

partment, University of Minnesota,

USA. He has been with IBM since Sep-

tember 2005. Dr. Bekas‘ main research

interests span cognitive computing,

massive scale analytics and energy

aware algorithms and architectures. Dr.

Bekas is a recipient of the PRACE 2012

award and the ACM Gordon Bell 2013

and 2015 prizes.

PANEL DISCUSSION

MODERATION

Costas Bekas is managing the Foundations

of Cognitive Computing group at IBM Re-

search-Zurich. He is also a keynote speaker at

this conference and presented in the respec-

tive section of this booklet.

Nathan Hubbard is the Director of Digital

and Personalized Health Care Partnering for

Roche, where he is responsible for the iden-

tification and execution of digital healthcare

partnerships as part of the implementation

of Roche’s personalized health care strategy.

Nathan joined Roche in August of 2016 and

has completed business development collab-

orations with Vital Art and Science and GNS

Healthcare among others. Nathan has held

a number of roles across the pharmaceutical

value chain within strategy, business devel-

opment, finance, sales, and marketing with

a focus on oncology and neurology. Nathan

received an MBA from Stanford University,

where he focused on general management,

and holds a BA in Economics with minors

in English Literature and Psychology from

DePauw University.

Denis Schapiro studied Technical Biology at

the Universities of Stuttgart and Harvard work-

ing with Alfred Goldberg (Proteome Dynam-

ics) and Peter Sorger (Signalling in Rheuma-

toid Arthritis). Moving from wet lab to dry lab,

he joined the Complex Systems Modelling

group as an intern at Bayer AG.

Afterwards he joined the group of Bernd

Bodenmiller (University of Zurich) to develop

computational and experimental methods for

spatial proteomics. The developed Imaging

Mass Cytometry™ technology as well as the

analysis software histoCAT™ are both today

routinely used in world leading research insti-

tutes for basic and translational research.

He was awarded the first UZH BioEntrepre-

neur-Fellowship to combine Cytometry and

Pathology in a user-friendly computational

framework which he is currently using as a

platform for biomarker discovery based on

spatial localization of cell types, tissue organi-

zation and cellular neighbourhoods.

Effy Vayena is a Professor of Bioethics at the

Swiss Institute of Technology and a Visiting

Professor at the Center for Bioethics at Har-

vard Medical School and a Faculty Associate

at the Berkman Klein Center for Internet &

Society at Harvard University. She is a social

historian with a PhD in Medical History from

University of Minnesota and a renowned ex-

pert at the intersection of medicine, data, and

ethics. Her work focuses on societal issues

of data and technology. At the University of

Zurich, she cofounded and coordinated the

PhD program in Biomedical Ethics and Law.

She also founded the Health Ethics and Poli-

cy Lab to tackle pressing questions that arise

through technological advances in healthcare

and research. She has previously worked with

the WHO, Wellcome Trust, OECD, Common-

wealth Fund, Chatham House, and academ-

ic institutions and governments around the

world.

Barnaby Skinner studied history at the University

of Basel, focussing on the Industrial Revolution in the

19th Century and its social and economic impacts. As

a journalist writing for the «SonntagsZeitung» and the

«Tages-Anzeiger» he has shifted his attention to the

Digital Revolution, using data driven technologies to

tell stories and explore, how the Internet is impacting

society.

MissionThe Swiss Industry Science Fund (SISF) promotes scientific excellence in research and education in Switzerland, within the scope of its member companies.

OrganizationThe SISF is an unregistered partnership of the following member companies (listed alphabetically): BASF, Novartis, Roche, Syngenta.They meet quarterly to discuss and decide on applications for support.The SISF provides financial support for selected initiatives meeting the following criteria:• Selected scientific conferences, organizations, awards and special events in basic and applied research,

for education and further development of students and scientists.• Scientific areas covered include biology, chemistry and associated disciplines, with a focus on pharma-

ceutical R&D, life sciences and material sciences.• Events must take place in Switzerland or nearby regions, and call for a substantial and active participati-

on of Swiss-based scientists.• Preference will be given to events open to broad, rather than local participation.

More information can be found at www.sisf.info.

YOUR NOTES